Three-month weight loss on a GLP-1 medication is usually about 3% to 8% of your starting body weight. Some people lose less, while strong early responders may lose 5% to 10% or more.
The 2026 FDA prescribing information for Wegovy and Zepbound shows why early results vary: both medications start at low doses and increase gradually.
| Starting weight | 3% loss | 5% loss | 8% loss | 10% loss |
|---|---|---|---|---|
| 150 lb | 4.5 lb | 7.5 lb | 12 lb | 15 lb |
| 200 lb | 6 lb | 10 lb | 16 lb | 20 lb |
| 250 lb | 7.5 lb | 12.5 lb | 20 lb | 25 lb |
| 300 lb | 9 lb | 15 lb | 24 lb | 30 lb |
These are planning estimates, not guaranteed results. The medication, starting weight, dose, appetite response, eating pattern, physical activity, diabetes status and side effects can all affect the outcome.
Why Weight Loss Is Often Slower During the First 3 Months
People usually start GLP-1 medications at a low dose. The dose then increases gradually to reduce the risk of nausea, vomiting and other gastrointestinal side effects.
Wegovy contains semaglutide. Its injection schedule starts at 0.25 mg once a week for 4 weeks. The dose then increases to 0.5 mg, 1 mg and 1.7 mg at four-week intervals. The usual maintenance dose is reached after the first 16 weeks.
Zepbound contains tirzepatide. Treatment starts at 2.5 mg once a week for 4 weeks. The dose then increases gradually. In clinical trials, dose escalation could take up to 20 weeks before the maintenance phase.
After 12 weeks, a person may still be taking an introductory or intermediate dose. A slow first month does not necessarily mean the medication will not work.
What Clinical Research Suggests About Early Weight Loss
Early weight loss varies from person to person. A post hoc analysis of tirzepatide and semaglutide treatment compared average weekly weight-loss rates during the first 12 weeks among rapid and non-rapid responders.
In that analysis, tirzepatide users lost about 0.56 kg to 1.00 kg per week during the first 12 weeks. Semaglutide users lost about 0.47 kg to 0.86 kg per week, depending on the response group. These figures are not personal forecasts because researchers divided participants into groups after observing their early results.
A reasonable way to interpret the first 3 months is:
- 0% to 3% loss: This can happen during the adjustment period, particularly with a low appetite response, side effects or missed doses.
- 3% to 8% loss: This is a practical early target for many people starting treatment.
- 5% to 10% loss: This is possible for people who respond strongly during the first 12 weeks.
- More than 10% loss: This can happen, but it should not be treated as the expected result for everyone.
How 3-Month Results Compare With Long-Term Results
The largest weight-loss trials measured results over much longer periods than 3 months.
In the STEP 1 trial, adults taking semaglutide 2.4 mg once a week lost an average of 14.9% of their starting body weight after 68 weeks. The placebo group, which also received lifestyle intervention, lost 2.4%.
Zepbound's pivotal weight-loss studies assessed results after 72 weeks. The studies included a dose-escalation period of up to 20 weeks and at least 52 weeks at a maintenance dose. Those results cannot be used directly to predict what someone will lose in only 12 weeks.
Three-month weight loss is an early progress check, not a final result. Weight loss may continue after the medication reaches a tolerated maintenance dose.
What Can Improve Your Result?
Medication works best alongside a reduced-calorie eating pattern and regular physical activity. The following habits may support weight loss:
- Eat enough protein and fiber to help preserve muscle and manage hunger.
- Choose smaller meals if the medication causes early fullness.
- Drink enough fluids, especially if nausea, vomiting or diarrhea occurs.
- Include resistance training to support muscle mass.
- Track weekly weight averages instead of reacting to daily changes.
- Increase the dose only according to your prescriber's instructions.
Do not increase the dose faster than prescribed. Faster escalation can increase gastrointestinal side effects without guaranteeing faster fat loss.
When to Contact Your Prescriber
Contact your healthcare professional if you have persistent vomiting, severe abdominal pain, signs of dehydration, or an inability to eat or drink. Seek medical guidance for symptoms that could indicate a serious reaction.
The FDA prescribing information for Wegovy and Zepbound includes warnings about severe gastrointestinal reactions, pancreatitis, gallbladder disease and kidney injury related to volume depletion.
Pregnancy requires immediate medical guidance because these medications may cause fetal harm. Wegovy is also contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Bottom Line
For many people, losing 3% to 8% of starting body weight in 3 months is a reasonable planning range. Losing 5% to 10% can happen, particularly in strong early responders, but a slower result does not automatically mean the medication has failed.
The first 12 weeks are largely a dose-adjustment period. Results are usually more meaningful when evaluated over 6 to 18 months rather than after only 3 months.